Background: Biofilm-associated Pseudomonas aeruginosa infections in cystic fibrosis have limited treatment options. Ceftolozane/tazobactam is a relatively recently available β-lactam/β-lactamase inhibitor combination that has been shown to have preserved activity against difficult-to-treat P. aeruginosa isolates. However, the effectiveness of ceftolozane/tazobactam (C/T), in monotherapy and combination with tobramycin (TOB), has not yet been characterised for the pharmacokinetics […]
Tag Archives | 2023
Preliminary development of a semi physiologically-based pharmacokinetic model for rocuronium
January 18, 2023
Authors David J.R. Foster (1), Clare Hayes-Bradley (2,3)
Affiliations 1. Australian Centre for Precision Health, University of South Australia, 2. Aeromedical Operations, 3. Blacktown & Mount Druitt Hospitals
Presentation type Oral
Presenters David J.R. Foster
Introduction: Rocuronium is commonly used to temporarily paralyse the muscles of the jaw and voice box to facilitate intubation. In the first few minutes after rapid IV administration, cardiac output (CO) is a primary determinant of arterial blood concentrations, and thus effect, for many drugs. In particular, CO can be significantly altered in emergency patients. […]